Therapy Detail

Therapy Name ACY-1215
Therapy Description

Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ricolinostat ACY-1215 HDAC Inhibitor 34 Ricolinostat (ACY-1215) is a selective inhibitor of HDAC6, which may decrease tumor cell viability and reduce tumor growth, alone or in combination with other agents (PMID: 22262760, PMID: 27926524).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown multiple myeloma no benefit ACY-1215 Phase Ib/II Actionable In a Phase Ib/II trial, Ricolinostat (ACY-1215) as a single therapy did not result in toxicity nor clinical benefit in multiple myeloma patients (PMID: 28053023). 28053023
Clinical Trial Phase Therapies Title Recruitment Status
NCT02091063 Phase Ib/II ACY-1215 ACY-1215 for Relapsed/Refractory Lymphoid Malignancies Recruiting
NCT01323751 Phase Ib/II Bortezomib + Dexamethasone ACY-1215 Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Completed